Lilly reports positive clinical data for migraine therapy galcanezumab

Lilly has announced new clinical trial data that demonstrates the benefits offered by its investigational migraine therapy galcanezumab.

The drug was able to meet its primary endpoint in three phase III studies, EVOLVE-1, EVOLVE-2 and REGAIN, by demonstrating statistically significant reductions in the number of monthly migraine headache days compared to placebo at both studied doses.

EVOLVE-1 and EVOLVE-2 were six-month trials evaluating the safety and efficacy of two doses of galcanezumab administered subcutaneously, while REGAIN was a shorter study conducted over three months.

Detailed data from these studies will be presented at scientific meetings later this year, with the results to be submitted to peer-reviewed journals.

Dr Robert Conley, global development leader for migraine therapeutics at Lilly, said: "The topline results from this phase III data are encouraging and reaffirm the potential for galcanezumab to provide a new option for people living with migraine."

Galcanezumab is also being evaluated for the treatment of cluster headaches, with phase III trial results expected in 2018.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.